0001628280-26-034244
SEC filingModest revenue and gross profit gains from Evolve product sales were overshadowed by wider operating losses, as higher expenses outpaced topline growth during the commercialization phase.
Revenue for Q1 FY2026 reached $493,000, up 1.6% from $485,000 in the prior year quarter. This modest increase reflects sales growth in Evolve product offerings—Evolve Rat and Evolve Mouse—partially offset by an expected decline in ContraPest units sold, as noted in management's discussion. The shift underscores execution of the company's commercialization strategy emphasizing fertility control products in the growing non-poison rodent control market, driven by regulatory restrictions on traditional rodenticides and demand for sustainable alternatives.
Despite topline gains, operating income deteriorated to -$2.1 million from -$1.7 million, a 27.4% widening driven by elevated operating expenses outpacing revenue growth. The company continues to invest in marketing, sales, and operational efficiency amid its investment phase, with expenses expected to rise in connection with fertility control commercialization. Net income followed suit at -$2.1 million versus -$1.7 million last year, though diluted EPS improved 69.5% to -$0.39, benefiting from a reduced share count.
Looking ahead, cash and equivalents as of March 31, 2026, combined with anticipated revenue, should fund operations into Q3 2027 assuming continued strategy execution, planned expenses, and stable working capital. Domestic sourcing mitigates tariff risks, positioning SenesTech to capitalize on market opportunities while managing liquidity.